Dr Jiwon Oh (University of Toronto, Canada) caught up with touchNEUROLOGY to discuss investigating fenebrutinib as a potential Multiple Sclerosis therapy.
The abstract entitled: ‘The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What is the rationale for the use of BTK inhibitors in MS? (0:14)
- How does fenebrutinib differ from other agents in its class in terms of suitability as an MS therapy? (1:20)
- What autoimmune indications were included in your safety analysis? (3:41)
- What were the findings of this analysis? (4:30)
- What were the conclusions in terms of potential use at high doses in MS patients? (6:51)
Disclosures:
Jiwon Oh has received personal compensation for consulting or speaking from EMD-Serono, Sanofi-Genzyme, Biogen-Idec, Novartis, BMS, and Roche, and has received research funding from the MS Society of Canada, the National MS Society, Brain Canada, Biogen-Idec, Roche, and EMD-Serono.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
